NVO news sentiment

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales

Novo Nordisk CEO sees ‘long runway’ for weight-loss drugs as obesity grips America

Novo Nordisk CEO Mike Doustdar believes there is a significant future for weight-loss drugs like Wegovy, as only a small percentage of eligible Americans currently use GLP-1 medications despite over 100 million suffering from obesity. Doustdar highlighted that wider adoption of these drugs could not only improve individual health but also lead to reduced healthcare costs and increased economic productivity through a healthier workforce. He stressed that the industry is still in its "early innings" regarding the potential impact of these treatments.

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinica

Novo Nordisk and AWS bring agentic AI into drug discovery

Novo Nordisk is expanding its collaboration with AWS to integrate agentic AI into its drug discovery processes, including target identification and therapy design. AWS will serve as Novo Nordisk's preferred cloud provider and strategic AI partner, with a co-innovation hub established in London to facilitate direct collaboration between AWS engineers and Novo Nordisk scientists. This partnership aims to accelerate drug discovery timelines by streamlining computational and laboratory research workflows, leveraging AWS's AI services like Amazon Bio Discovery and Amazon Bedrock AgentCore.

Novo Nordisk partners Amazon on London AI hub

Novo Nordisk has partnered with Amazon Web Services (AWS) to establish an AI co-innovation hub in London, aiming to accelerate drug discovery from target identification to human trials. This collaboration makes AWS Novo Nordisk's primary cloud and strategic AI partner, integrating AWS engineers and AI specialists with Novo Nordisk's R&D teams. The initiative seeks to leverage AI tools like Amazon Bio Discovery and Bedrock to enhance drug development and diversify Novo Nordisk's pipeline beyond its core diabetes and obesity focus.

Novo’s Catalent plant ditched in FDA refiling of SMA drug

Scholar Rock has removed Novo Nordisk’s legacy Catalent facility as a contract manufacturer for its spinal muscular atrophy drug, apitegromab, in its FDA refiling due to ongoing issues at the plant. This decision follows multiple FDA citations and an "Official Action Indicated" designation for the Catalent site, which has also impacted other companies like Regeneron and Incyte. Scholar Rock is now relying solely on a second U.S.-based fill-finish facility for its FDA application, though the Catalent site is still included in its European application.

Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and

Novo Nordisk A/S Q2 Earnings Call Highlights

Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower realized prices, manufacturing costs and currency effects reduced the adjusted gross margin to 78.2% from 82.7%. Oral Wegovy drove obesity-treatment momentum. The U.S. pill surpassed 5 million prescriptions and captured about 90% of the oral obesity-drug market, while roughly 80% of users were new to GLP-1 treatments; internatio

‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Karsten Munk Knudsen, CFO of Novo Nordisk, described his nine years on the leadership team as a "roller coaster," navigating periods of low growth, hyper-growth fueled by demand for their obesity drugs, and subsequent growth slowdown. He emphasized the pressure and responsibility of steering the high-profile pharma company. Despite mixed data for their new drug CagriSema, Knudsen remains optimistic about its prospects as a competitive diabetes product.

Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market

A U.S. federal judge has dismissed an antitrust lawsuit against Eli Lilly and Novo Nordisk filed by compounding pharmacy Strive Specialties. Strive had accused the pharmaceutical giants of illegally blocking access to customized versions of their GLP-1 weight-loss drugs through exclusive deals with telehealth providers. The judge ruled that Strive failed to plausibly allege a product market and did not adequately show how it was harmed, stating that antitrust laws protect competition, not individual competitors.

Novo Nordisk: what the Danish pharma giant does and makes

Novo Nordisk is a Danish pharmaceutical giant founded in 1923, primarily known for its diabetes and obesity treatments, including the blockbuster drugs Ozempic and Wegovy. The company's core business revolves around insulin and GLP-1 receptor agonists like semaglutide, with a significant portion of its revenue coming from its diabetes and obesity care segment. Novo Nordisk is controlled by the Novo Nordisk Foundation, which influences its long-term strategy, and its shares are traded on the Nasdaq Copenhagen exchange and NYSE.

How Novo Nordisk’s CEO Says He Is Shifting the Company’s Perspective

Novo Nordisk (NYSE:NVO) Stock May Be Below Fair Value On ZEUS Trial Fallout

Lilly climbs, Novo falls as obesity drug battle intensifies

Eli Lilly's shares climbed while Novo Nordisk's dropped this week following their respective earnings reports, intensifying the battle for the lucrative GLP-1 obesity and diabetes treatment market. Novo Nordisk faced disappointment with its experimental CagriSema failing to match Lilly's tirzepatide in a trial and its Wegovy pill sales falling short of analyst estimates. In contrast, Lilly exceeded Wall Street expectations, attributing its strong performance to the continued growth of its best-selling drug, tirzepatide.

Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says

Novo Nordisk's CEO, Maziar Mike Doustdar, stated that the company is not currently in a position to pursue large-scale, transformative mergers and acquisitions, preferring bolt-on acquisitions to complement its internal R&D. This comes as Novo Nordisk faces mixed Q2 results, pipeline setbacks, and aims to close the gap with competitor Eli Lilly, largely relying on its Wegovy pill for growth. While the company upgraded its guidance for the full year, analysts remain unexcited about its stock prospects.